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Background: The purpose of this study was to formulate and evaluate nano lipid vesicles of 
methotrexate (MTX) for its anti-rheumatoid activity.
Methods: In this study the principle of both active as well as passive targeting using MTX-
loaded stealth liposomes as per the magic gun approach was followed. Stealth liposomes of 
MTX were prepared by thin-film hydration method using a PEGylated phospholipid-like DSPE-
MPEG 2000. Similarly, conventional liposomes were prepared using phospholipids like DPPC 
and DSPC. Conventional liposomes were coated with a hydrophilic biocompatible polymer like 
chitosan. They were investigated for their physical properties and in vitro release profile. Further, 
in vivo screening of the formulations for their anti-rheumatoid efficacy was carried out in rats. 
Rheumatoid arthritis was induced in male Wistar-Lewis rats using complete Freund’s adjuvant 
(1 mg/mL Mycobacterium tuberculosis, heat killed in mineral oil).
Results: It was found that chitosan coating of the conventional liposomes increased the 
physical stability of the liposomal suspension as well as its entrapment efficiency. The size of 
the unsonicated lipid vesicles was found to be in the range of 8–10 µm, and the sonicated lipid 
vesicles in the range of 210–260 nm, with good polydispersity index. Further, chitosan-coated 
conventional liposomes and the PEGylated liposomes released the drug for a prolonged period 
of time, compared to the uncoated conventional liposomes. It was found that there was a sig-
nificant reduction in edema volume in the rat group administered with the test stealth liposomal 
formulations and chitosan-coated conventional liposomes (PEGylated and chitosan-coated 
conventional) compared to that of the control and standard (administered with free MTX) 
group of rats. PEGylated liposomes showed almost equal efficacy as that of the chitosan-coated 
conventional liposomes.
Conclusion: Lipid nano vesicles of MTX can be administered by intravenous route, whereby 
the drug selectively reaches the target site with reduced toxicity to other organs.
Keywords: methotrexate, stealth liposomes, conventional liposomes, chitosan coating, targeted 
delivery, anti-rheumatoid efficacy
Introduction
Liposomes are lipid vesicles which are under extensive investigation as drug carriers 
for improving the delivery of therapeutic agents. They are composed of relatively 
  biocompatible and biodegradable materials, and consist of an aqueous volume 
entrapped by one or more bilayers of natural and/or synthetic lipids. Liposomes were 
discovered in the early 1960s by Bangham and collaegues (Bangham et al, 1965) and 
subsequently became the most extensively explored drug delivery system.1
The availability of liposomes in the market (Doxil® [doxorubicin, Sequus Pharma-
ceuticals USA]; DaunoXome® [daunorubicin, Sequus Pharmaceuticals USA], ableet, International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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amphotech [amphotericin B, Sequus Pharmaceuticals USA], 
and am-BiSome® [amphotericin B, NeXstar Pharmaceuti-
cals], etc) makes it obvious that liposome technologies can 
mature into highly sophisticated pharmaceutical products. 
There was a continuous increase in sales of these products 
in 1999. Total sales of over one-quarter of a billion dollars 
makes the development of other liposome-based pharma-
ceutical products attractive.2 They are microscopic aggre-
gates of highly ordered lipid molecules which are normally 
dispersed in a hydrophilic solvent, typically water.3 Lipid 
vesicles are micro-particulate or colloidal carriers, usually 
0.05–5.0 µm in diameter which form spontaneously when 
certain lipids are hydrated in aqueous media.4 Drugs with 
widely varying lipophilicities can be encapsulated in lipid 
vesicles, either in the phospholipid bilayer, in the entrapped 
aqueous volume, or at the bilayer interface. Drugs used in 
the treatment of diseases like cancer and   rheumatoid arthri-
tis usually have a narrow therapeutic index (TI) and can be 
highly toxic to normal tissues. The toxicity of these drugs 
may be minimized by decreasing delivery to critical normal 
organs. It has been shown that even a small   reduction in 
distribution of the drug to critical organs by encapsulation 
in lipid vesicles can significantly reduce the drug   toxicity. 
Lipid vesicles are taken up poorly by tissues such as heart, 
kidney, and GI tract, which are major sites for toxic side 
effects of a variety of antineoplastic drugs. Thus lipid 
vesicle formulations may improve the TI by altering the 
bio-  distribution of drugs away from drug sensitive normal 
tissues.5 Methotrexate (MTX) is the most commonly used 
DMARD (disease modifying anti-rheumatic drug) for the 
treatment of rheumatoid arthritis. MTX has gained popu-
larity among doctors as a second-line drug because of its 
  effectiveness. MTX as an antimetabolite-folate antagonist 
is also used in the treatment of metastatic breast cancer. The 
drug side-effect profile includes mouth sores, stomach upset, 
and low white blood counts. MTX can cause severe toxicity 
of the liver, kidneys, and bone marrow, which require regu-
lar monitoring with blood tests. It can cause headache and 
  drowsiness, itching, skin rash, dizziness, and hair loss. A dry, 
non-productive cough can be a result of rare lung toxicity, 
which often results in cessation of therapy. To decrease the 
systemic side-effects and optimize the local anti-  inflammatory 
effect, intra-articular free MTX has been administered, but the 
efficacy was low due to rapid clearance of the drug from the 
joint cavity.6 This can be overcome by encapsulating MTX 
in lipid vesicles with the aim of increasing the retention time 
in the joint and with the added advantage of targeting the 
damaged synovial membrane in the joints. PEGylated lipid 
vesicles of MTX can be prepared which are “stealth” lipid 
vesicles that evade detection and destruction by phagocytes 
by virtue of their cloaks of hydrated PEG (polyethylene 
glycol) molecules. The other main advantage of PEGylated 
lipid vesicles lies in the possibility of active-targeted delivery 
of drugs to the tissues or organs that need them most. Not 
only does this maximize delivery efficiency for the agent in 
question, but it also minimizes the chances of toxicity to other 
organs. The objective of the present study is to formulate and 
optimize the stable conventional and PEGylated lipid vesicles 
of MTX and in vivo screening of the formulations in rats for 
its anti-rheumatoid efficacy.
Materials and methods
Materials
MTX was gifted by Khandelwal Laboratories Pvt Ltd,   Mumbai, 
India. DSPE-MPEG 2000 (1,2-Distearoyl-phosphatidyleth-
anolamine-methyl-polyethyleneglycol conjugate-2000) was 
a gift from Lipoid GmBH, Ludwigshafen, Germany. DSPC 
(1,2-Distearoyl-sn-glycero-3-phosphocholine) and DPPC 
(1,2-Dipalmitoyl-sn-glycero-3-phosphocholine) were also 
gifted as samples from Genzyme Pharmaceuticals, Liestal, 
Switzerland. Cholesterol was obtained from HiMedia 
  Laboratories Pvt Ltd, Mumbai, India. All other chemicals 
used were of analytical grade.
Preparation of lipid nano vesicles
Lipid nano vesicles were prepared by the passive-loading 
technique thin-film hydration method as per the method 
described by Bangham et al in 1965.4 The molar ratios of 
lipids (phospholipids-MPEG-DSPE/DSPC/DPPC and cho-
lesterol) were accurately weighed and dissolved in a minimal 
quantity (about 2 mL) of a mixture of chloroform:methanol 
(2:1) in a 250 mL round bottom flask with a ground glass 
neck to obtain a clear solution (typically lipid solutions were 
prepared at 10–20 mg lipid/mL of the organic   solvent). The 
round bottom flask was rotated at 60 rpm while immersed 
in a water bath with a thermostat set at a temperature above 
the phase transition temperature (Tm) of the phospholipids 
to obtain a thin dry lipid film. Hydration of the dry lipid 
film was accomplished by adding the MTX in PBS pH 7.4 
  buffer at a concentration of 1.5 mg/mL and the tempera-
ture of the hydrating medium was maintained above the 
gel-liquid crystal transition temperature (Tm) of the phos-
pholipid with the highest Tm, before adding to the dry lipid. 
Once a stable multi lamellar vesicles (MLV) suspension was 
produced, it was then subjected to ultra-probe sonication 
by transferring the suspension into a glass vial. Sonication International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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was done in two cycles – first the liposomal suspension was 
sonicated at 80% amplitude with a pulse of 0.5 cycles per 
second for a period of 3 minutes, followed by 3 minutes 
rest (excess heat may be generated during probe sonication, 
which may damage the lipids). After 3 minutes, the second 
cycle was processed for 3 minutes at 80% amplitude with 
0.5-second pulse for another 3 minutes. After sonication, 
the heterogeneous liposomal suspension of SUVs (small, 
unilamellar vesicles) was converted to a homogenous sus-
pension of SUVs by passing it through a 0.22 µm syringe 
filter, which further improves the polydispersibility index 
(PDI) and also achieved the sterilization of the liposomal 
suspension which can be administered intravenously (IV). 
Different molar ratios of lipids were used to formulate the 
lipid vesicles (DSPC/DPCC:cholesterol, 10:1, 10:2 for 
conventional lipid vesicles and for stealth lipid vesicles 
DSPC/DPCC:MPEG-DSPE:cholesterol, 10:0.1:2; 10:0.2:2; 
10:0.4:2; 10:0.5:2, etc) and drug-to-lipid ratio were tested 
(D/L; 0.2, 0.25, 0.3, 0.35, 0.4, 0.5, etc).
coating of the lipid vesicles containing 
the drug with a cationic hydrophilic 
polymer chitosan
Coating of MLVs was done by mixing an aliquot of the 
  liposomal suspension with the chitosan solution in 0.5% 
v/v of glacial acetic acid.7 Chitosan solution (containing 
0.1% w/v, 0.2% w/v, 0.4% w/v, and 0.6% w/v) was added 
drop-wise into the respective lipid vesicle suspensions under 
controlled stirring (50 rpm) using a magnetic stirrer at room 
temperature. After coating the lipid vesicles, the samples 
were incubated at 10°C in the refrigerator for 1 hour in a 
50 mL beaker. The concentration of chitosan solution was 
optimized to 0.1% w/v. This was sonicated at 80% amplitude, 
with 0.5-second pulses for 3 minutes with a rest period of 
3 minutes, followed by sonication for a further 3 minutes.
The optimized ratios of DSPC:cholesterol (F3) or 
DPCC:cholesterol (F4) are 10:2, respectively for both con-
ventional lipid vesicles.
In vitro characterization of the lipid 
vesicles
Differential scanning calorimetry (Dsc)
DSC of the phospholipid samples (solid mixture) was 
performed in order to determine the exact transition tempera-
ture (Tm [°C]) of the mixtures of phospholipids: (1) mixture 
of DSPC with MPEG 2000-DSPE, (2) mixture of DPPC with 
MPEG 2000-DSPE.
Optical photomicroscopy
The MLV suspension (100 µL) was placed on a clean glass 
slide; a cover slip was placed on it, taking care to prevent air 
bubble formation. This was focused under 45× magnification 
using a MOTIC digital photographic microscope to view the 
MLVs. The size (in µm) of the MLVs was also measured 
using the microscopic scale (Figure 1).
Average particle size and size distribution
Average particle size (in nanometers) and size   distribution 
(as the PDI) of the liposomal suspension (SUVs) was   measured 
using a Malvern nano zetasizer instrument (  Zetasizer 3000 
HAS; Malvern Instruments Ltd,   Worcestershire, UK).
Zeta potential
Zeta potential measurement of the chitosan-coated   liposomal 
formulation (SUVs) was done by using a Malvern nano 
zetasizer instrument (Zetasizer 3000 HAS; Malvern 
  Instruments Ltd, Worcestershire, UK).
Entrapment efficiency (EE)
Entrapment efficiency of MTX in the lipid vesicles was 
determined as follows: After sonication, 1 mL of the   liposomal 
suspension (SUVs) was taken in a 1 mL micro centrifuge 
tube, centrifuged at 80,000 rpm for 1 hour at 4°C in a cold 
centrifuge to get a white pellet of SUVs which settled at the 
bottom of the centrifuge tube. The supernatant was separated 
as it contained unentrapped MTX which is highly soluble in 
PBS pH 7.4 buffer, using a micropipette. To the remaining 
pellet in the centrifuge tube, 500 µL of 0.1 N NaOH (as MTX 
is highly soluble in 0.1 N NaOH) was added and vortexed thor-
oughly for 3 minutes. After vortexing, a white suspension was 
obtained and 1 mL of this suspension was transferred to a test 
tube using a   micropipette. To this 5 mL, methanol was added 
which resulted in a clear   solution; this was further vortexed for 
2 minutes (to ensure that the lipid vesicles are lysed completely 
Figure 1 Optical photomicrograph of MLVs under 40× magnification.
Abbreviation: MLV, multi lamellar vesicles.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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to release the drug).8 This solution (1 mL) was further diluted 
with methanol and the absorbance was determined using a 
UV-VIS spectrophotometer (UV-1700 Pharmaspec; Shimadzu 
Corporation, Kyoto, Japan) at λmax of 303 nm.
The entrapment efficiency (EE) was calculated using the 
following formula:
 
Drug in pellet (entrapped drug) (mg/mL)
Total drug added (mg g/mL)
× 100
In vitro release studies
The liposomal suspension (1 mL) of SUVs was placed 
on one side of the Sigma dialysis membrane (MWCO – 
20 kDa) in a vertical Franz diffusion cell. The other side of 
the membrane was in contact with the dissolution medium. 
The entire   dissolution assembly was placed on a magnetic 
stirrer at 37°C. The dissolution medium was 50 mL of PBS 
pH 7.4 buffer. Aliquots (5 mL) of dissolution medium was 
withdrawn at different time intervals: 5, 10, 15, 30, 45, 
and 60 minutes, and 2, 4, 8, 12, and 24 hours. Whenever 
a sample was withdrawn, an equal volume of fresh dis-
solution medium was added to the beaker to maintain a 
constant volume. Drug concentrations in the dissolution 
medium were determined using UV spectrophotometry, 
at λmax of 303 nm. All the experiments were carried out 
in triplicate.
stability studies
For stability testing, the sonicated liposomal suspension 
of SUVs was stored away from light in sealed 2 mL micro 
centrifuge eppendroff tubes in the refrigerator (4°C–8°C) 
for 3 months.
Sampling was done by withdrawing 100 µL of the 
supernatant using a micropipette at days 2, 4, 10, 20, 40, 
45, 60, 80, and 90. Suitable dilutions were made with PBS 
pH 7.4 buffer. Whenever a sample was withdrawn, UV 
a  bsorbance was determined at λmax of 303 nm and drug 
content was estimated.
In vivo studies
Anti-rheumatoid efficacy studies
Male Wistar-Lewis  rats  (5–6  weeks  old  weighing 
200 ± 10 g) were used. Animal groups were selected with 
the same initial body weight. Animals were kept under 
controlled environmental conditions (22°C ± 0.5°C with 
relative humidity 40%–60%), alternate light–dark cycles, 
food and water. The animals were allowed to acclimate 
for 1 week before the experiment. They were housed in 
cages in which the floor was covered with sawdust to 
minimize the possibility of painful contact with a hard 
surface. Adjuvant arthritis was induced as per the method 
described by Pearson and Wood, by injecting 0.6 mL (1 mg/
mL) of complete Freund’s adjuvant (CFA, heat killed and 
dried, Mycobacterium tuberculosis in 0.85 mL mineral oil, 
0.15 mL mannide mono-oleate) to the subplantar region of 
the left hind paw.
The parameter of interest of adjuvant-induced arthritis 
is the swelling of the right paw, which is typically estab-
lished in 19 days after induction. Rats were divided into 
five groups containing six animals in each group: normal 
control   (neither induction of arthritis nor treatment with 
MTX), CFA-control (induction of arthritis with CFA), CFA+ 
standard, CFA+ test 1, and CFA+ test 2. CFA-control group 
received only 0.6 mL of complete Freund’s adjuvant. The 
CFA+ test 1 group of rats received CFA to the left hind 
paw + PEGylated MTX liposomal formulation (DSPC: 
MPEG-DSPE: CH-10:0.2:2 at a dose of 0.13 mg/kg MTX 
iv), the CFA+ test 2 group of rats received chitosan-coated 
conventional lipid vesicles (DSPC: CH-10:2 at a dose of 
0.13 mg/kg MTX iv), and the standard group received MTX 
solution (0.13 mL of MTX injection [15 mg/mL] equivalent 
to 0.13 mg MTX IV) as a single IV injection through the 
tail vein on day 0. The onset day of arthritis was determined 
as the day on which right hind paw swelling or its redness 
was detectable. For determining the arthritic reaction, a 
marking was made in the tebio-tarsal joint of the right and 
left hind paws and the paw volume (in mL) of each paw was 
determined on day 0, 5, 10, 21, 26, and 29 after induction 
of adjuvant arthritis, using a water displacement digital 
plethysmometer. The severity of the induced adjuvant dis-
ease was determined by measurement of the non-injected 
right paw (secondary lesion) with a plethysmometer and 
by measuring the body weight every 3 days after arthritis 
induction.9,10
  % Decrease in edema volume = 1 − VT/VC × 100
where ‘VT’ is edema volume of treated animal and ‘VC’ 
edema volume of control animal.
Arthritis assessments
The rats were assessed daily for signs of arthritis between 
days 7 and 25, after the administration of CFA. During 
the treatment with MTX formulations, paw volume was 
measured every second day with a plethysmometer. Blood 
was collected from the animals by retro-orbital puncture International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
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for estimation of biochemical parameters. Serum aspartate 
transaminase (AST) as SGOT levels, alanine transaminase 
(ALT) as SGPT levels, alkaline phosphatase (ALP), and 
total proteins (TP) were assessed. This study was performed 
not only to assess the extent of recovery of animals from 
the effects of CFA treatment, but also to study the level of 
side effects of MTX, as reported earlier in the introduction. 
The animals were sacrificed by cervical dislocation for the 
determination of organ weight.11
statistical analysis
The data were presented as mean ± SEM one-way analysis 
of variance (ANOVA) followed by post Dunnet multiple 
comparison tests to compare the efficacy of the formulations 
using GraphPad Prism software (v 4.03.354; GraphPad 
  Software, Inc, San Diego, CA).
Results and discussion
Preparation of lipid vesicles
Lipid vesicles were prepared by the thin-film hydration 
method as per the method described by Bangham et al, 
1965. Drug to lipid ratio was optimized as 0.2. ie, D/L = 0.2, 
means 1/L = 0.2 or 1/0.2 = L, hence L = 5, ie, drug:lipid 
ratio is 1:5. The hydration volume was optimized to 6 mL, 
based on the amount of phospholipid taken. The hydra-
tion medium contained 9 mg of MTX dissolved in 6 mL 
PBS 7.4. The optimized ratios of stealth lipid vesicles are, 
F1;DSPC:MPEG-DSPE:CH-10: 0.2:2 and F2;DPPC:MPEG-
DSPE:CH-10: 0.2:2. 
Differential scanning calorimetry (Dsc) 
analysis
The phase transition temperature (Tm) of the mixture of DSPC 
with MPEG-2000 DSPE was found to be 76.28°C, whereas 
Tm for the mixture of DPPC with MPEG-2000 DSPE was 
found to be 69.28°C (Figure 2).
Particle size analysis
Particle size analysis of the sonicated lipid vesicles – SUVs 
was determined using a Malvern zetasizer instrument. It 
was found that the average particle size of stealth lipid 
vesicles (F1 and F2) was found to be 210 nm, whereas the 
average particle size of conventional chitosan-coated lipid 
vesicles (F3-coated and F4-coated) was found to be 253 nm. 
The size range for unsonicated lipid vesicles was found to be 
around 8–10 µL (Figure 1). The PDI remained in the range 
of 0.2–0.3, indicating good dispersion of uniformly sized 
lipid vesicles.
Zeta potential analysis
The zeta potential of the coated formulations was compared 
with that of the uncoated formulation; it was found that the 
zeta potential of the chitosan-coated formulation – F3 was 
positive (+39.5 mv), compared to the zeta potential of the 
uncoated formulation – F3 which was found to be negative 
(−2.78 mv). This finding indicated the successful coating of 
the formulation with chitosan.
Entrapment efficiency
Entrapment efficiency of the lipid vesicles was determined 
after sonication. Entrapment efficiency of the SUVs was 
determined by lysing the SUVs in methanol. Entrapment 
of the drug in the uncoated lipid vesicles was found to be 
in the range 23%–31%, whereas for coated lipid vesicles it 
was in the range 43%–53%. The increase in size of the lipid 
vesicles also increased the entrapment efficiency. It was found 
that the chitosan-coated conventional lipid vesicles showed 
significantly higher entrapment efficiency compared to that 
of the PEGylated lipid vesicles and the uncoated conventional 
lipid vesicles. This indicated that chitosan coating of the 
conventional lipid vesicles increases entrapment efficiency. 
More recently, the most accepted theory with respect to lipid 
vesicles–chitosan interaction was that chitosan covers the sur-
face of the liposomal formulation.12,13 In this study, chitosan 
coating of the conventional lipid vesicles produced cationic 
lipid vesicles (CHITOSOMES). Chitosan has strong affin-
ity for the phospholipid of the vesicle bilayer and covers the 
surface of the lipid vesicles by forming an ion complex with 
phosphatidyl choline in the liposomal formulation. MTX, 
being negatively charged, does not compete with positively 
charged chitosan to interact with the phospholipid of the 
bilayer. Hence, there is a possibility of interaction between 
the drug and chitosan as well as chitosan and phospholipids, 
and thus, there was increased retention of the drug, thereby 
increasing entrapment efficiency.
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Figure 2 Differential scanning calorimetry (Dsc) graph for DsPc:MPeg 2000-DsPe 
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In vitro release studies
The in vitro release profile of the drug is given in Figure 3. 
The initial burst release was observed for all formula-
tions, owing to their surface hydrophilicity. PEGylated 
(F1 and F2) and chitosan-coated formulations (F3-coated 
and F4-coated) showed a significantly higher burst release 
compared to the other formulations. However, PEGylated 
formulations showed a higher burst release compared to that 
of the chitosan-coated formulations. This burst release was 
observed due to the presence of the drug on the surface in the 
adsorbed form. All the PEGylated formulations (F1 and F2) 
and the chitosan-coated formulations (F3 and F4) released 
the drug for 24 hours. PEGylated formulations (F1 and F2) 
also released the drug for a period of 24 hours. The conven-
tional formulations F3 and F4 released the drug for a period 
of 12 hours. Formulation F3 released 88.41% of the drug in 
12 hours, whereas formulation F4 released 90.45% of the 
drug in 12 hours. Formulation F3-coated (conventional-
coated) released 70.63% of the drug in 24 hours, whereas for-
mulation F4-coated (conventional-coated) released 75.67% 
of the drug in 24 hours. These results indicate that the release 
of MTX follows a slow release profile, which suggests that 
it takes time for MTX to be released once encapsulated in 
the lipid vesicles because the lipid bilayers are stabilized by 
cholesterol. Thus, a depot effect could be achieved using lipid 
vesicles, especially in the coated liposomal formulations.
Anti-rheumatoid and anti-arthritic 
efficacy
Adjuvant-induced arthritis in rats is a well-established 
experimental model that has features similar to human 
rheumatoid arthritis. In addition, it is a good chronic inflam-
matory model for the development of potential analgesic 
and/or anti-inflammatory drugs useful for arthritis treatment. 
Adjuvant arthritis is characterized by chronic   proliferative and 
inflammatory reactions in synovial membranes,   producing 
pain, disability, and eventually destruction of joints. Although 
the etiology of this disease is unknown, it is thought that 
autoimmune processes are involved. Experimental evidence 
suggests that an autoimmune process involving T lymphocytes 
is responsible for the generation of adjuvant arthritis.14,15
In the present study, the challenge with CFA resulted 
in mono-articular arthritis, which is evident from the 
significantly increased paw volume in arthritis control, 
whereas the reduction of paw volume with the test-1 and 
test-2 formulations after 21 days indicated the effective-
ness of the anti-inflammatory activity of the formulations. 
The arthritic lesions, ie, swelling of the right hind paw and 
lesions on the forepaw, appeared from day 19 onwards in 
CFA-control rats and the standard group of rats, whereas the 
lesions were observed from day 21, after arthritis induction 
in the test group (both CFA+ test 1 and CFA+ test 2) of rats 
treated with the lipid vesicle formulations (Figures 3–6).
The following observations were made during the study 
(Tables 1–3): in the CFA-control group of rats, the total edema 
volume of four paws gradually increased as the days passed. 
Volume displaced reached a peak on day 21, followed by a 
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Figure 3 Comparison of release profile of various formulations.
Figure 4 cFA+ control group rat showing severe inflammation of the left hind paw 
with secondary lesion on the forepaw with moderate inflammation of the other 
hind paw on day 26.
Abbreviation: cFA, complete Freund’s adjuvant.
Figure 5 cFA+ standard group rat showing moderate inflammation of the left hind 
paw with a moderate lesion on the forepaw on day 26.
Abbreviation: cFA, complete Freund’s adjuvant.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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gradual decrease for CFA-treated groups CFA+ test 1, CFA+ 
test 2, and the standard group of rats. Rats treated with CFA+ 
test 1 formulation showed a significantly lower peak value 
on day 21 compared with that of the CFA+ test 2, and the 
standard groups, whereas the rat group treated with the CFA+ 
test 2 formulation showed a peak lower than the standard. 
The CFA+ test 1 group of rats showed a highly significant 
(P , 0.01) percentage decrease in edema volume on day 26 
and day 29 compared to the CFA-control group of rats. The 
CFA+ test 2 group of rats showed a significant (P , 0.05) 
percentage decrease in edema volume on days 26 and 29, 
compared to the CFA-control group of rats. Formulation 
CFA+ test 1 (PEGylated lipid vesicles) showed the highest 
anti-rheumatoid efficacy, followed by CFA+ test 2 (chitosan-
coated liposomal formulation), and the standard-free MTX 
(the effectiveness of polymer-coated lipid vesicles is not as 
high as PEG-derivative-containing lipid vesicles in terms of 
retention in the bloodstream after iv injection).13 However, 
formulation CFA+ test 2 showed an anti-rheumatoid efficacy 
better than that of the standard. Assessment of the serum levels 
of AST, ALT, and ALP provides an excellent and simple tool 
to measure the anti-arthritic activity of the drug. The activi-
ties of aminotransferases and ALP increased significantly in 
arthritic rats, since these are good indices of liver and kidney 
impairment, which is also considered a feature of adjuvant 
arthritis. Serum AST and ALT has been reported to play a vital 
role in the formation of biologically active chemical media-
tors such as bradykinins in inflammatory process. Increased 
levels of serum ALP in adjuvant-induced arthritic rats can be 
due to increases in the liver and bone fractions or due to the 
increased levels of both isoenzymes. This in turn indicates 
localized bone erosion and peri-articular osteopenia, as the 
enzyme is released into the circulation during the course of 
bone formation and resorption.16 It was reported that adjuvant 
administration in rats immunologically alters the hepatic bio-
chemistry. Most of the literature has suggested an increase in 
the baseline serum ALP level. It has also reported a decrease 
in serum total protein in rheumatoid arthritis.16
In the present study, the challenge with CFA significantly 
(P , 0.001) elevated the serum AST and ALT estimated as 
serum SGOT and SGPT level and decreased the total protein 
level (Table 4), whereas the effect on ALP was insignificant 
(P , 0.001) in arthritis control. It was suggested that the 
development of inflammation in CFA-induced arthritis 
may be related to the biochemical changes in hepatic 
enzymes. The serum SGOT and SGPT levels (P , 0.01 level 
significance compared to CFA control) in animal groups 
treated with MTX lipid vesicle formulations (CFA+ test 1 
Figure 6 cFA+ test 2 group rat showing only moderate inflammation of the left 
hind paw on day 26.
Abbreviation: cFA, complete Freund’s adjuvant.
Figure 7 cFA+ test 1 group rat showing complete recovery of the paws with 
completely suppressed secondary lesion and minimal paw inflammation on day 26.
Abbreviation: cFA, complete Freund’s adjuvant.
Table 1 Volume of water displaced in the plethysmograph
Animal  
groups
Weight (g) Edema volume (mL)a
Day 0 Day 5 Day 10 Day 21 Day 26 Day 29
cFA-control 210 ± 10 5.476 ± 0.07 5.883 ± 0.06 5.883 ± 0.06 6.183 ± 0.04 6.333 ± 0.06 6.383 ± 0.06
cFA+ test 1  
Pegylated
210 ± 10 5.367 ± 0.15 5.817 ± 0.07 5.783 ± 0.09 5.650 ± 0.17 5.50 ± 0.103 5.383 ± 0.21
cFA+ test 2 
ch coated
210 ± 10 5.283 ± 0.13 5.667 ± 0.10 5.800 ± 0.09 5.733 ± 0.14 5.850 ± 0.11 5.350 ± 0.12
standard 210 ± 10 5.300 ± 0.13 5.750 ± 0.07 5.833 ± 0.09 5.983 ± 0.15 5.883 ± 0.14 5.517 ± 0.21
Note: aTabular values represent mean ± standard error of the mean.
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and CFA+ test 2), indicated the effectiveness of the lipid 
vesicles in inflammatory conditions. However, the level of 
SGOT and SGPT in animal groups treated with standard 
formulations of MTX remained above the normal level 
(upper limit is 60 units/L). This may be due to the fact that 
MTX itself may cause damage to the liver as reported ear-
lier. Though the extent of inflammation is reduced with the 
standard formulation of MTX, the effect of MTX on liver 
was reflected in the level of serum SGOT and SGPT.
The effect of MTX formulations on spleen and kidney was 
further confirmed by changes in their weight. The challenge 
with CFA significantly increased the weight of kidney, spleen, 
and liver organs in arthritis control. The MTX standard for-
mulation significantly (P , 0.05) increased the liver weight. 
However, the effect on kidney weight and spleen weight was 
insignificant (P , 0.05; Table 5). The effect of MTX in the 
form of lipid vesicles on organ weight, especially the weight 
of the liver indicated the safety margin of the formulations 
(Table 5). The spleen is an important lymphoid organ involved 
in immune responses against all types of antigens that appear 
in the circulation and it provides a readily available source 
of cells known to be involved in adjuvant arthritis. Increased 
cellularity in the spleen of adjuvant injected rats engendered 
interest as to the potential for  concomitant classical antibody 
formation where the increased antibody titer in arthritic ani-
mals further supports the hyper immune status by humoral 
immunity. Further, the increase in spleen weight in the adju-
vant-induced arthritic rats has been reported to be associated 
with splenomegaly, generalized lymphadenopathy, and altered 
hepatic function.17 Injection of CFA significantly increased 
spleen weight in arthritis control and showed no effect on 
spleen weight with MTX formulations (Table 5). Thus, these 
findings suggested that the inhibition of lymphocytes and 
decreased immunological response may be responsible for 
the anti-arthritic potential of MTX formulations.
Hence in treating rheumatoid arthritis, instead of using 
intra-articular (can lead to joint inflammation with pain) 
or oral delivery of MTX, (where MTX gets uniformly 
distributed to all the tissues in the body leading to unwanted 
adverse effects), alternative delivery of MTX using stealth 
lipid vesicles can be administered by IV route, whereby the 
drug selectively reaches the target site with reduced toxicity to 
other organs and may offer reduced doses, decreasing dosing 
frequency, thereby improving patient compliance.
stability study
As the liposomes are thermodynamically unstable systems, 
they tend to fuse and grow into bigger vesicles, resulting in 
Table 2 edema volume of different groups of animals on various 
days
Animal groups Edema volume (mL)
Day 21 Day 26 Day 29
cFA+ test 1 
(Pegylated)
0.283 0.133 0.016
cFA+ test 2 
(ch coated)
0.45 0.567 0.067
standard 0.683 0.583 0.217
cFA-control 0.707 0.857 0.907
Note: edema volume = final edema volume − initial edema volume.
Abbreviation: cFA, complete Freund’s adjuvant.
Table 3 Percentage decrease in edema volume in various animal 
groups
Animal groups Decrease in edema volume (%)
Day 21 Day 26 Day 29
cFA+ test 1 
(Pegylated)
59.9* 84.4** 98.2**
cFA+ test 2 
(ch coated)
36.35 33.8* 92.6**
standard 3.39 31.97* 76.07*
Notes: *P , 0.05, significant; **P , 0.01, highly significant.
Abbreviation: cFA, complete Freund’s adjuvant.
Table 4 effect of MTX formulations on serum enzyme level and 
total protein level of cFA-induced arthritic animals
Animal groups Units/L Total protein 
g/dL SGOT SGPT ALP
cFA+ test 1 
(Pegylated)
55** 50** 184* 6.4**
cFA+ test 2 
(ch-coated)
60** 57** 185* 6.4**
standard 85** 87** 183* 6.5**
cFA-control 105*** 98*** 182* 5.3***
Normal control 47 52 177 6.2
Notes: *P , 0.05 significant; **P , 0.01, highly significant; ***P . 0.05, insignificant.
Abbreviation: cFA, complete Freund’s adjuvant.
Table 5 effect of MTX formulations on organ weight of cFA-
induced arthritic animals
Animal groups g/100 g body weight
Liver Kidney Spleen
cFA+ test 1 
(Pegylated)
3.6*** 0.61*** 0.48***
cFA+ test 2 
(ch-coated)
3.5*** 0.62*** 0.47***
standard 3.9* 0.62*** 0.48***
cFA-control 4.2** 0.80** 0.59**
Normal control 3.6 0.60 0.47
Notes: *P , 0.05 significant; **P , 0.01, highly significant; ***P . 0.05, insignificant.
Abbreviation: cFA, complete Freund’s adjuvant.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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breakage of the liposomes on storage, which poses a problem 
of drug leakage from the vesicles. Unsaturated phospholipids 
undergo oxidation easily. Hence, in the present work, only 
saturated phospholipids like DPPC, DSPC, and MPEG-DSPE 
were used to formulate the liposomes, to avoid oxidation. 
Therefore, no antioxidants such as α-tocopherol were used. 
Since the saturated phospholipids have a high Tm they exhib-
ited good physical stability. The physical stability of sonicated 
liposomes on storage was studied by monitoring the amount 
of leaked drug from liposomes into the supernatant and by 
the size of the liposomes. The presence of divalent metal ions 
such as calcium and magnesium in the aqueous buffer causes 
the aggregation of liposomes, particularly those with negative 
charge. Therefore, aqueous buffer used for the preparation of 
liposomes was made using double-distilled water.
The stability data of liposomes at 4°C–8°C is given in 
Table 6. Stealth liposomes (F1 and F2) were found to be 
more stable than the conventional liposomes (F3 and F4) and 
showed much less drug leakage compared to the conventional 
liposomes. However, chitosan-coated liposomes (F3-coated 
and F4-coated) were highly stable compared to the stealth 
and conventional liposomes. Chitosan-coated liposomes 
also showed significantly less drug leakage when compared 
to the stealth and conventional liposomes. Chitosan-coated 
liposomes showed the best physical stability because of the 
steric repulsion created by the positive surface charge on 
the liposomes leading to steric stabilization of the colloidal 
suspension.
Conclusion
MTX-loaded nano lipid vesicles were prepared for the treat-
ment of rheumatoid arthritis and compared with the MTX 
standard (solution form). The nano lipid vesicles enhanced the 
targeting of MTX in vivo, and effectively promoted the reten-
tion of MTX in the inflamed tissue. It can be concluded that in 
treating rheumatoid arthritis, lipid nano vesicles of MTX can 
be more effective than intra-articular or oral delivery of MTX, 
which can lead to joint inflammation with pain and in the 
case of oral delivery (where MTX gets uniformly distributed 
to all the tissues in the body), can lead to unwanted adverse 
effects. Delivery of MTX using stealth lipid vesicles can be 
administered by iv route, whereby the drug selectively reaches 
the target site with reduced toxicity to other organs.
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